title: Mechanistic clues in the protective effect of ellagic acid against apoptosis and decreased mitochondrial respiratory enzyme activities in myocardial infarcted rats.
abstract: Our previous study described the cardioprotective effects of ellagic acid in an isoproterenol-induced myocardial infarction model. In this study, we are reporting the mechanism of protective action of ellagic acid with respect to apoptosis and mitochondrial respiratory enzymes. Ellagic acid (7.5 and 15 mg/kg) was administered orally as a pretreatment for 10 days. Then, isoproterenol (100 mg/kg) was injected subcutaneously to rats at an interval of 24 h for 2 days. Myocardial infarction was quantified by planimetry. Apoptosis was measured by apoptotic gene expressions. The levels of mitochondrial respiratory enzymes were also measured. Isoproterenol-induced myocardial infarcted rats showed increased infarct size, a decrease in myocardial expression of the Bcl-2 gene and an increase in myocardial expression of the BAX gene. Fas ligand and caspases were markedly elevated along with compromised respiratory marker enzymes in isoproterenol-induced rats. Ellagic acid pretreatment reduced the infarct size, regulated apoptotic gene expressions and enhanced the activities of mitochondrial respiratory marker enzymes and cell viability, thereby protecting the myocardium against isoproterenol-induced myocardial infarction. The decreased infarct size associated with inhibited apoptosis and increased respiratory marker enzymes provide insight on the role of ellagic acid in antiapoptotic mechanism, and it may be the reason for its cardioprotective activity.
authors.affiliation: SASTRA University, Thirumalaisamudram, Thanjavur, Tamil Nadu, India.
authors.forename: M
authors.initials: M
authors.lastname: Mari Kannan
authors.forename: S
authors.initials: S
authors.lastname: Darlin Quine
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001696:Biomechanical Phenomena; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004610:Ellagic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D004789:Enzyme Activation; D008297:Male; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology*; D009203:Myocardial Infarction / Q000201:enzymology* / Q000503:physiopathology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002316:Cardiotonic Agents; D004610:Ellagic Acid